Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Frequently asked questions
What sector does Kailera Therapeutics, Inc. Common Stock (KLRA) operate in?
Kailera Therapeutics, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Kailera Therapeutics, Inc. Common Stock (KLRA) current stock price?
As of the latest data, Kailera Therapeutics, Inc. Common Stock stock price is $13.13, with a previous close of $12.77. Kailera Therapeutics, Inc. Common Stock gained $0.36 in the last trading session, representing a 2.82% increase.
What is Kailera Therapeutics, Inc. Common Stock (KLRA) current market capitalization?
Kailera Therapeutics, Inc. Common Stock market cap is approximately 1.70 billion.
What is Kailera Therapeutics, Inc. Common Stock (KLRA) Earnings Per Share (EPS)?
The trailing EPS is -$2.25, and the forward EPS is -$4.30.
What is Kailera Therapeutics, Inc. Common Stock (KLRA) EBITDA?
Kailera Therapeutics, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -111.31 million.
Does Kailera Therapeutics, Inc. Common Stock (KLRA) pay dividends?
No. Kailera Therapeutics, Inc. Common Stock does not pay a dividend.
What is Kailera Therapeutics, Inc. Common Stock (KLRA) beta (volatility) score?
Kailera Therapeutics, Inc. Common Stock has a beta of 0.017, indicating lower volatility than the overall market.
